NO20012567L - Azepinoindole derivatives, preparation and use thereof - Google Patents

Azepinoindole derivatives, preparation and use thereof

Info

Publication number
NO20012567L
NO20012567L NO20012567A NO20012567A NO20012567L NO 20012567 L NO20012567 L NO 20012567L NO 20012567 A NO20012567 A NO 20012567A NO 20012567 A NO20012567 A NO 20012567A NO 20012567 L NO20012567 L NO 20012567L
Authority
NO
Norway
Prior art keywords
preparation
azepinoindole derivatives
azepinoindole
derivatives
forms
Prior art date
Application number
NO20012567A
Other languages
Norwegian (no)
Other versions
NO20012567D0 (en
Inventor
Wilfred Lubisch
Michael Kock
Thomas Hoeger
Sabine Schult
Roland Grandel
Reinhold Mueller
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/en
Priority claimed from DE10039610A external-priority patent/DE10039610A1/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20012567D0 publication Critical patent/NO20012567D0/en
Publication of NO20012567L publication Critical patent/NO20012567L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet forbindelser med formel l og deres automere former, mulige enantiomere og diastereomere former, og deres promedikamenter, samt fremstilling og anvendelse derav.Compounds of formula I and their automated forms, possible enantiomeric and diastereomeric forms, and their prodrugs, and their preparation and use are disclosed.

NO20012567A 1999-09-28 2001-05-25 Azepinoindole derivatives, preparation and use thereof NO20012567L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (en) 1999-09-28 1999-09-28 Benzodiazepine derivatives, their production and use
DE10039610A DE10039610A1 (en) 2000-08-09 2000-08-09 Azepinoindole derivatives are PARP inhibitors and are useful for the treatment of neurodegenerative diseases, ischemia, tumor, septic shock, inflammation, rheumatic diseases, ARDS and diabetes mellitus
PCT/EP2000/009024 WO2001023390A2 (en) 1999-09-28 2000-09-15 Azepinoindole derivatives, the production and use thereof

Publications (2)

Publication Number Publication Date
NO20012567D0 NO20012567D0 (en) 2001-05-25
NO20012567L true NO20012567L (en) 2001-06-25

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012567A NO20012567L (en) 1999-09-28 2001-05-25 Azepinoindole derivatives, preparation and use thereof

Country Status (17)

Country Link
EP (1) EP1183259A2 (en)
JP (1) JP2003510328A (en)
KR (1) KR20010087401A (en)
CN (1) CN1374961A (en)
AU (1) AU1271201A (en)
BG (1) BG105650A (en)
BR (1) BR0007174A (en)
CA (1) CA2352194A1 (en)
CZ (1) CZ20012373A3 (en)
HK (1) HK1048999A1 (en)
HU (1) HUP0104917A3 (en)
IL (1) IL143349A0 (en)
NO (1) NO20012567L (en)
PL (1) PL347885A1 (en)
SK (1) SK8842001A3 (en)
TR (1) TR200101499T1 (en)
WO (1) WO2001023390A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE60142921D1 (en) 2000-12-01 2010-10-07 Eisai Inc AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (en) 2002-04-30 2011-01-27 Kudos Pharm Ltd phthalazinone
US7786344B2 (en) 2002-07-26 2010-08-31 Basf Plant Science Gmbh Selection method
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
TWI338000B (en) 2003-12-01 2011-03-01 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN102925479A (en) 2005-03-08 2013-02-13 巴斯福植物科学有限公司 Expression enhancing intron sequences
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (en) 2006-10-17 2008-05-31 Kudos Pharm Ltd SUBSTITUTED DERIVATIVES OF 2H-FTALAZIN-1-ONA, ITS CRYSTAL FORMS, PREPARATION PROCESS AND APPLICATIONS
WO2009034326A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (en) 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (en) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011064750A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
EP2504439B1 (en) 2009-11-27 2016-03-02 BASF Plant Science Company GmbH Optimized endonucleases and uses thereof
CN102762726A (en) 2009-11-27 2012-10-31 巴斯夫植物科学有限公司 Chimeric endonucleases and uses thereof
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CA2993270C (en) 2015-07-23 2019-07-16 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
US11161865B2 (en) * 2017-05-24 2021-11-02 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3919495A4 (en) * 2019-02-02 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analogue as parp inhibitor
WO2021018298A1 (en) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Indolo-seven-membered acyloxime compounds as parp inhibitors
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023537220A (en) * 2020-07-31 2023-08-31 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Crystals of indoloheptaacyl oxime analogues as PARP inhibitors and method for producing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AP1538A (en) * 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
ECSP003637A (en) * 1999-08-31 2002-03-25 Agouron Pharma TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES

Also Published As

Publication number Publication date
EP1183259A2 (en) 2002-03-06
TR200101499T1 (en) 2002-09-23
WO2001023390A3 (en) 2001-12-27
NO20012567D0 (en) 2001-05-25
SK8842001A3 (en) 2002-01-07
BG105650A (en) 2002-02-28
AU1271201A (en) 2001-04-30
PL347885A1 (en) 2002-04-22
KR20010087401A (en) 2001-09-15
JP2003510328A (en) 2003-03-18
HUP0104917A3 (en) 2002-12-28
HUP0104917A2 (en) 2002-04-29
BR0007174A (en) 2001-09-04
CA2352194A1 (en) 2001-04-05
IL143349A0 (en) 2002-04-21
CN1374961A (en) 2002-10-16
WO2001023390A2 (en) 2001-04-05
HK1048999A1 (en) 2003-04-25
CZ20012373A3 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
NO20012567L (en) Azepinoindole derivatives, preparation and use thereof
NO20021379L (en) Benzodiazepine derivatives, preparation and use thereof
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
DE60038481D1 (en) CRYSTALLINE FORM OF (R) -2-ÄÄÄ3-METHYL-4- (2,2,2-TRIFLUORETHOXY) -2-PYRIDINYL METHYLÜSULFINYLÜ-1H-BENZIMIDAZOLE
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
EE200200710A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
TR200201205T2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
NO20021833L (en) Draft insert for insert
NO20015156D0 (en) 5-Pyridyl-1,3-Azole Compounds, Process for Production of the Same and Their Use
NO20073465L (en) Benzothiazole derivatives
NO20060665L (en) N-substituted pyrazolyl-amidyl-benzimidazolyl C-kit inhibitors
MA26812A1 (en) PYRIMIDINE-2,4,6-TRIONES INHIBITORS OF METALLOPROTEINASES
DE60005054D1 (en) Quinuclidine ACRYLAMIDE
PT1159279E (en) 4-OXO-4,7-DIHYDROTIENE-2,3-B | PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
PT923554E (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
NO990662L (en) Thrombin inhibitors
NO20005264L (en) Heterocyclic substituted amides, their preparation and use
TR200403436T2 (en) Crystalline 1-methylcarbapenem derivatives.
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
BR9813719A (en) Therapeutic agents
IL150357A0 (en) Substituted piperazine derivatives as mtp inhibitors
DK1463731T3 (en) Dibenzodiazepine derivatives, their preparation and use
NO20003960D0 (en) Salts of paroxetine
NO20006547D0 (en) Salts of paroxetine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application